Quest Diagnostics
DGX
$135.56
Share price
1.13%
Change (1 day)
-0.47%
Change (1 year)
Categories
Quest Diagnostics is an American clinical laboratory company offering access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders and employment and court ordered drug testing.
Revenue for Quest Diagnostics (DGX)
Revenue in 2023 (TTM): $9.60 B
According to Quest Diagnostics 's latest financial reports the company's current revenue (TTM) is $9.60 B. In 2022 the company made a revenue of $9.88 B a decrease over the years 2021 revenue that were of $10.78 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Quest Diagnostics from 2001 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $9.60 B | -2.83% |
| 2022 | $9.88 B | -8.39% |
| 2021 | $10.78 B | 14.32% |
| 2020 | $9.43 B | 22.15% |
| 2019 | $7.72 B | 2.59% |
| 2018 | $7.53 B | -2.31% |
| 2017 | $7.70 B | 2.58% |
| 2016 | $7.51 B | 0.29% |
| 2015 | $7.49 B | 0.78% |
| 2014 | $7.43 B | 4.05% |
| 2013 | $7.14 B | -4.33% |
| 2012 | $7.46 B | -0.56% |
| 2011 | $7.51 B | 1.92% |
| 2010 | $7.36 B | -1.16% |
| 2009 | $7.45 B | 2.84% |
| 2008 | $7.24 B | 8.12% |
| 2007 | $6.70 B | 6.9% |
| 2006 | $6.27 B | 13.96% |
| 2005 | $5.50 B | 7.36% |
| 2004 | $5.12 B | 8.2% |
| 2003 | $4.73 B | 15.33% |
| 2002 | $4.10 B | 13.24% |
| 2001 | $3.62 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 LabCorp LH | $14.75 B | 53.65% | 🇺🇸 USA |
 Translate Bio
TBIO.defunct | $0.22 B | -97.66% | 🇺🇸 USA |
 Psychemedics PMD | $25.24 M | -99.74% | 🇺🇸 USA |
 NeoGenomics
NEO | $0.52 B | -94.48% | 🇺🇸 USA |
 Qiagen QGEN | $1.99 B | -79.19% | 🇳🇱 Netherlands |
 Enzo Biochem ENZ | $81.12 M | -99.16% | 🇺🇸 USA |